



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

27 March 2013
EMA/CHMP/122529/2013
Press Office

Guidelines and concept papers

Adopted during the CHMP meeting 18-21 March 2013

The guidelines and concept papers which have been adopted during this meeting of the Committee for Medicinal Products for Human Use (CHMP) will be published shortly on the European Medicines Agency's website under [Regulatory/Human/Scientific guidelines](#). Documents for public consultation will also be available under [Document search/Public consultations](#).

Biologics Working Party (BWP)

Reference number	Document	Status
EMA/CHMP/BWP/85290/2012	Guideline on the declaration of the quantitative composition/labelling of biological medicinal products that contain modified proteins as active substance	6-month public consultation

Blood Products Working Party (BPWP)

Reference number	Document	Status
EMA/CHMP/BPWP/153137/2011	Reflection paper on Immune Tolerance Induction in haemophilia A patients with inhibitors	adopted

Central Nervous System Working Party (CNSWP)

Reference number	Document	Status
EMA/CHMP/40896/2013	Concept paper on the development of medicinal products for the treatment of Autism Spectrum Disorder	3-month public consultation



Committee for Medicinal Products for Human Use (CHMP)

Reference number	Document	Status
EMA/CHMP/BWP/99698/2007	Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure	2-week public consultation

Oncology Working Party

Reference number	Document	Status
EMA/CHMP/153191/2013	Guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia	6-month public consultation

Pharmacokinetics Working Party (PKWP)

Reference number	Document	Status
EMA/CHMP/806058/2009/Rev. 02	Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product	adopted¹

¹ The document was adopted by CHMP after the February 2013 Plenary meeting